Bad blood: secrets and lies in a Silicon Valley startup
(Book)
Author:
Published:
New York : Alfred A. Knopf, 2018.
ISBN:
9781524731656, 152473165X
Status:
2nd Floor- Adult Books
338.761 CAR
Description
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
Copies
Location
Call Number
Status
Last Check-In
2nd Floor- Adult Books
338.761 CAR
Check Shelf
Jul 10, 2023
More Details
Format:
Book
Edition:
First edition.
Physical Desc:
x, 339 pages ; 25 cm.
Language:
English
Notes
Bibliography
Includes bibliographical references and index.
Description
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--,Provided by publisher.
Description
"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--,Provided by publisher.
Reviews from GoodReads
Loading GoodReads Reviews.
Citations
APA Citation (style guide)
Carreyrou, J. (2018). Bad blood: secrets and lies in a Silicon Valley startup. First edition. New York, Alfred A. Knopf.
Chicago / Turabian - Author Date Citation (style guide)Carreyrou, John. 2018. Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Alfred A. Knopf.
Chicago / Turabian - Humanities Citation (style guide)Carreyrou, John, Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, Alfred A. Knopf, 2018.
MLA Citation (style guide)Carreyrou, John. Bad Blood: Secrets and Lies in a Silicon Valley Startup. First edition. New York, Alfred A. Knopf, 2018.
Note! Citation formats are based on standards as of July 2022. Citations contain only title, author, edition, publisher, and year published. Citations should be used as a guideline and should be double checked for accuracy.
Staff View
Grouped Work ID:
baef1559-c66a-350a-94da-a1c38154f67e
Record Information
| Last Sierra Extract Time | Jul 12, 2023 08:37:02 AM |
|---|---|
| Last File Modification Time | Jul 13, 2023 04:07:36 AM |
| Last Grouped Work Modification Time | Sep 28, 2023 03:51:55 AM |
MARC Record
| LEADER | 05047cam a2200505 i 4500 | ||
|---|---|---|---|
| 001 | ocm1029779381 | ||
| 003 | OCoLC | ||
| 005 | 20180531092347.0 | ||
| 008 | 180316t20182018nyu b 001 0 eng | ||
| 010 | |a 2018000263 | ||
| 019 | |a 1019646846 | ||
| 020 | |a 9781524731656|q hardcover | ||
| 020 | |a 152473165X|q hardcover | ||
| 035 | |a (OCoLC)1029779381|z (OCoLC)1019646846 | ||
| 037 | |b Random House Inc, Attn Order Entry 400 Hahn rd, Westminster, MD, USA, 21157|n SAN 201-3975 | ||
| 040 | |a DLC|b eng|e rda|c DLC|d OCLCO|d SSH|d OCLCF|d JSE|d FEM|d QQ3|d JTH|d YDX|d CZA|d OCLCO|d JQM|d JVK | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 049 | |a JVKA | ||
| 050 | 0 | 0 | |a HD9995.H423|b U627 2018 |
| 082 | 0 | 0 | |a 338.7/681761|2 23 |
| 092 | |a 338.761 CAR | ||
| 100 | 1 | |a Carreyrou, John,|e author. | |
| 245 | 1 | 0 | |a Bad blood :|b secrets and lies in a Silicon Valley startup /|c John Carreyrou. |
| 250 | |a First edition. | ||
| 264 | 1 | |a New York :|b Alfred A. Knopf,|c 2018. | |
| 264 | 4 | |c ©2018. | |
| 300 | |a x, 339 pages ;|c 25 cm. | ||
| 336 | |a text|b txt|2 rdacontent. | ||
| 337 | |a unmediated|b n|2 rdamedia. | ||
| 338 | |a volume|b nc|2 rdacarrier. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\day -- Going live -- Unicorn -- The grandson -- Fame -- The hippocratic oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue. | |
| 520 | |a "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--|c Provided by publisher. | ||
| 520 | |a "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--|c Provided by publisher. | ||
| 610 | 2 | 0 | |a Theranos (Firm)|x History. |
| 650 | 0 | |a Hematologic equipment industry|z United States. | |
| 650 | 0 | |a Fraud|z United States. | |
| 907 | |a .b21492955|b 05-10-23|c 05-22-18 | ||
| 998 | |a an|b 05-31-18|c m|d a |e -|f eng|g nyu|h 0|i 1 | ||
| 938 | |a Brodart|b BROD|n 121475832 | ||
| 938 | |a YBP Library Services|b YANK|n 15083235 | ||
| 994 | |a C0|b JVK | ||
| 999 | |a rp | ||
| 945 | |g 1|i 31338006381336|j - - |k 07-11-23|l anf |o -|p $27.95|q -|r -|s - |t 0|u 13|v 7|w 1|x 0|y .i14112553|z 05-31-18 | ||
